# Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging

> **NCT01436604** · PHASE2 · TERMINATED · sponsor: **Centre Francois Baclesse** · enrollment: 19 (actual)

## Conditions studied

- Cancer, Breast
- LV Dysfunction

## Interventions

- **OTHER:** Cardiac MRI

## Key facts

- **NCT ID:** NCT01436604
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2015-08
- **Final completion:** 2017-05
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** lack of recruitment
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01436604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01436604, "Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01436604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*